BOS172722 (CCT289346) is a highly potent, selective and orally bioavailable inhibitor of spindle assembly checkpoint kinase MPS1. BOS172722 treatment alone induces significant sensitisation to death, particularly in highly proliferative triple negative breast cancer (TNBC) cell lines with compromised spindle assembly checkpoint activity. BOS172722 synergises with paclitaxel to induce gross chromosomal segregation defects caused by MPS1 inhibitormediated abrogation of the mitotic delay induced by paclitaxel treatment. In in vivo pharmacodynamic experiments, BOS172722 potently inhibits the spindle assembly checkpoint induced by paclitaxel in human tumour xenograft models of TNBC, as measured by inhibition of the phosphorylation of histone H3 and the phosphorylation of the MPS1 substrate, KNL1. This mechanistic synergy results in significant in vivo efficacy, with robust tumour regressions observed for the combination of BOS172722 and paclitaxel versus either agent alone in long-term efficacy studies in multiple human tumour xenograft TNBC models, including a patient-derived xenograft and a systemic metastasis model. The current target indication for BOS172722 is TNBC, based on their high sensitivity to MPS1 inhibition, the well-defined clinical patient population with high unmet need, and the synergy observed with paclitaxel.
Introduction
The key mechanism ensuring proper chromosome segregation during mitosis is the spindle assembly checkpoint (SAC), which monitors the correct bipolar attachment and tension of microtubules (MTs). When all microtubules have been properly attached to the kinetochores, the cells enter anaphase by releasing activators of the anaphase promoting complex/cyclosome (APC/C) (1, 2) . One of the pivotal proteins of the SAC is MPS1 kinase (also known as TTK). MPS1 is vital for the recruitment of kinetochore components, namely a complex of MAD2 and MAD1, to unattached kinetochores (3, 4) which in turn bind and lock the APC/C co-activator cdc20, keeping the APC/C inhibitory complex inactive. MPS1 is further essential for sustaining this inhibitory complex throughout mitosis (5) (6) (7) and for correcting improperly attached chromosomes (8) . Consequently, if MPS1 is inhibited, the time cells spend in mitosis is drastically reduced, resulting in elevated chromosome segregation errors and overall aneuploidy reaches detrimental levels (3, 6, 9, 10) . Whilst most cancers have a high frequency of aneuploidy (11, 12) and chromosome instability (CIN) is a common feature (13) (14) (15) , even these cells cannot tolerate aneuploidy beyond a certain threshold and increasing CIN has been shown to have a negative impact on their overall viability (16) (17) (18) . Thus, instant generation of unsustainable aneuploidy induced by MPS1 inhibition poses an attractive area for therapeutic intervention in cancer and several inhibitors have been previously reported (19) (20) (21) (22) (23) (24) (25) (26) .
Breast cancer comprises distinct subtypes (27) (28) (29) with both human epidermal growth receptor 2 (HER2) overexpressing and basal-like breast cancer, including triple negative breast cancers (TNBC), having a significantly worse prognosis than luminal and normal-like cancers (28, (30) (31) (32) . Within the distinct subgroups, TNBCs are associated with the highest proliferation rate and the expression of gene signatures associated with the cell cycle (29, 33, 34) . For these reasons, antimitotic chemotherapy seems to be a rational option in TNBC and we sought to identify synergistic combinations with established therapeutics in order to maximize benefit while minimizing the potential for the emergence of secondary resistant tumours.
Material and Methods

Reagents and Antibodies
Eribulin was purchased from Eisai Pharmaceuticals, HOECHST33342 and DAPI from Life Technologies. All other reagents were obtained from Sigma.
Cell culture
Cell lines were purchased from ATCC and DSMZ. In-house authentication of cell lines by SNP profiling was carried out and cultured cells were passaged for less than 6 months before replacement from early passage frozen stocks.
Cells were regularly screened for mycoplasma, using a PCR-based assay (VenorGem; Minerva Biolabs).
Cell based assays
We performed a High Throughput Screen at Horizon Discovery Inc. as described below. The endpoint readout of this assay is based upon quantitation of ATP as an indicator of viable cells (except when noted in Analyzer). Once cells reached expected doubling times, screening begins.
Cells are equilibrated in assay plates via centrifugation and placed in CO 2 incubators (attached to the Dosing Modules) at 37 o C for twenty-four hours before treatment. At the time of treatment, a set of assay plates (which do not receive treatment) are collected and ATP levels are measured by adding ATPLite (Perkin Elmer). These T-zero (T0) plates are read using ultrasensitive luminescence on Envision plate readers.
Assay plates are incubated with compound (10-point treatment) for 120 hours and are then analysed using ATPLite. All data points are collected via automated processes and are subject to quality control. GI 50 and Synergy was determined using Horizon's proprietary software, Chalice. Assay plates are accepted if they pass the following quality control standards: relative raw values are consistent throughout the entire experiment, Z-factor scores are greater than 0.6 and untreated/vehicle controls behave consistently on the plate. GI 50 determination in Breast Cancer cell lines was carried out in-house in 384 (Greiner Bio-One, #781091), as described below. Cells were seeded at individual optimal cell densities and drugs added using an Echo liquid handler (Labcyte). After 5 days cells were incubated with HOECHST 33342 stain (10g/ml) and Propidium iodide (1g/ml) and assays read on a Celigo Imaging Cytometer (Nexcelom) using the Dead&Total application. GI 50 s were assessed using GraphPad prism and a sigmoidal fit. For synergy screening in breast cancer cell lines, the respective drug concentrations were: 0.001 and 0.002M Paclitaxel, 0.0001 and 0.0002M eribulin, 0.002 and 0.004M doxorubicin and analysis was performed using the "Macsynergy™II" spreadsheet. In brief, cells were seeded at optimal densities in 96 well plates.
BOS172722 and Paclitaxel were added at a fixed ratio determined by the respective GI 50 s for each compound and cell line. Cell viability was assayed after 5 days using the MTT reagent and calculations were done using the Compusyn program.
Meso Scale Discovery (MSD) assay
In-house electrochemiluminescence (Meso Scale Discovery, MSD) assays were developed to measure tubulin acetylation and histone H3 
Flow cytometry
Flow cytometry to determine the cell cycle profile in HeLa cells after treatment with 100nM and 200nM BOS172722 for 24h, was performed as previously described (23) .
Metaphase spreads
Cells were seeded in 10 cm dishes. The next day, Paclitaxel or 0.25% DMSO was added. After 36h, cells were arrested using nocodazole (100ng/ml) and
further incubated for 4 hours. Mitotic cells were collected via mitotic shake off, pelleted, re-suspended in 0.75mM KCl and incubated at 37˚C for 8 minutes.
After centrifugation, cells were fixed using a -20˚C solution of 4:1 methanol:acetic acid. Cells were pelleted and fixative removed. 15l of cell suspension was dropped onto a glass slide and stained with 10g/ml DAPI.
Pictures were taken on a Zeiss Imager.D1 microscope equipped with an AxioCam MRm using Axiovision software (Zeiss).
Live cell imaging, immunofluorescence and immunoprecipitation
Analysis by immunofluorescence and time lapse microscopy as well as immunoprecipitations were performed as previously described (7) .
Immunohistochemistry and immunofluorescence in human tumour xenografts
Tumours were fixed in 10% neutral buffered formalin and embedded in paraffin. Phosphorylation of T875 on KNL1 was determined by immunohistochemistry. Heat-based antigen retrieval was performed by boiling the 4-mm-thick tissue sections in pH=6 citrate buffer (TCS Biosciences Ltd., HDS05, 1:100 dilution) for 5 min in a pressure cooker. The sections were incubated with a rabbit polyclonal T875-KNL1 antibody for 2h and detected using a Vectastain Elite ABC kit (Vector Laboratories) and DAB reagent (Dako). Nuclei of the cells were located by counterstaining the sections with
Harris' haematoxylin. The T875-KNL1 antibody was generated by immunizing rabbits with phosphorylated peptides CNDMDI(pT)KSYTI (Eurogentec). T875-KNL1 positive cells were quantified by manually counting positively stained cells in 8 random fields of the tumour section. Phosphorylation of Histone H3 was determined by immunofluorescence. Heat-based antigen retrieval was performed as described above, except that the slides were heated in the microwave for 10 min. The sections were incubated with rabbit polyclonal phistone H3 (S10) antibody (Millipore, 06-570) for 1h, then incubated with secondary goat anti-rabbit IgG (H+L) Alexa Fluor 488 (Invitrogen, A-11034) and counterstained with DAPI. For each section, 9 fluorescent images were captured and quantification of p-Histone H3 positive cells was done in CellProfiler software (www.cellprofiler.org). 
Real-Time quantitative PCR
RNA from cells was extracted using the
In vivo efficacy studies
The MDA-MB-468 and the OD-BRE-503 patient-derived xenograft studies were carried out at Oncodesign S.A., France. Statistical analyses of mean tumour volumes at randomisation were performed using ANOVA and pairwise tests were performed using the Bonferroni/Dunn correction in case of significant ANOVA results. A p-value < 0.05 was considered as significant.
For the metastatic model, MDA-MB-231 luciferase-expressing cells were injected iv in the tails of NOD SCID mice. Mice were dosed starting 6 days after tumour cell implantation, with Paclitaxel at 15mg/kg on days 0 (day 0 is 6 th day after tumour cell implantation), 7, 14 and 21 i.v. and BOS172722 at 30 and 40mg/kg p.o. on days 0+1, 7+8, 14+15 and 21+22 and tumour burden was assessed by whole body bioluminescent imaging (BLI). Animals were culled when they showed signs of deterioration due to tumour burden (body weight loss, rapid breathing). All animal studies were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and national guidelines (35) .
Results
BOS172722 is a novel, potent and orally bioavailable MPS1 inhibitor in biochemical and cellular assays
BOS172722 is a novel, orally bioavailable, potent and highly selective small molecule inhibitor of MPS1 kinase discovered from our in-house lead optimization studies on a pyridopyrimidine series of compounds ( Figure 1A ; (36) . In vitro kinase assays using purified recombinant MPS1 protein showed that BOS172722 inhibited MPS1 activity with IC 50 values of 0.004µM at low ATP (10µM) and 0.01µM, at high (1mM) ATP concentrations respectively ( Figure 1A ). The in vitro profiling of BOS172722 was tested in a wide panel of more than 400 kinases (36) . Only a small number of other kinases were inhibited by BOS172722, in particular JNK1, JNK2, JNK3 and LRRK2 at showing that BOS172722 is highly selective for MPS1 over these other kinases (36) . We have previously described the use of an in-house electrochemiluminescence (Meso Scale Discovery, MSD) assay to quantitatively measure MPS1 auto-phosphorylation in cells at T33/S37 sites (22, 23) . BOS172722 potently inhibited MPS1 T33/S37 auto-phosphorylation in MSD assay with IC 50 value of 0.06 ± 0.03 µM ( Figure 1A ). To prove that the observed inhibition of MPS1 phosphorylation it is not a consequence of a mitotic exit, nocodazole-arrested HCT116 cells, a colon cancer cell line sensitive to MPS1 inhibition widely used for MPS1 activity investigation (20) , were co-treated with BOS172722 and MG132 proteasome inhibitor to block exit from mitosis, for 2h. Nocodazole-induced MPS1 auto-phosphorylation on T33/S37 was completely inhibited by treatment with BOS172722, indicating that BOS172722 specifically inhibits the activity of MPS1 ( Figure 1B ). Next, HCT116 cells treated with different concentrations of BOS172722 for 24 and 48h were analysed for inhibition of histone H3 phosphorylation and PARP cleavage by immunoblotting. Histone H3 phosphorylation at Ser10 was inhibited in a time-dependent manner (Supplementary Figure S1A ). Induction of apoptotic cell death upon drug treatment also increased as determined by levels of cleaved PARP (Supplementary Figure S1A) . To identify the time that is required for BOS172722 to induce maximum effect on tumour cell growth inhibition, we performed wash-off experiments. HCT116 cells were treated with BOS172722 for 2 to 96h followed by the measurement of growth inhibition (GI 50 s) at 96h. We observed that 24h of treatment showed a comparable GI 50 to 96h treatment (Supplementary Figure S1B ), indicating that 24h of MPS1 inhibition is sufficient to achieve maximum growth inhibition in tumour cells.
Effects of BOS172722 on spindle assembly checkpoint activity and cell
cycle MPS1 activity is required for activation of SAC and inhibition of its activity results in SAC override and mis-segregation of chromosomes. In order to investigate the mechanism of action of BOS172722, we performed live cell imaging of H2B-mCherry-transfected HeLa cells, a model widely used to study mitosis. We measured time in mitosis and chromosome segregation defects after treatment with BOS172722. We found that treatment with 200nM of BOS172722 resulted in early mitotic exit of 11 minutes compared with 52 minutes for the untreated HeLa cells ( Figure 1C ) Figure   S1C ).
Cell proliferation rate and SAC activity are important indicators for BOS172722 potency
Prompted by the observation that PTEN-deficient cell lines are more sensitive to MPS1 inhibition (37) and in order to identify additional populations that may benefit from an MPS1 inhibitor, we tested 50 cancer cell lines, including 25 PTEN-proficient and 25 PTEN-deficient, with BOS172722 in a 5-day growth inhibition assay ( Supplementary Table S1A ). The results showed that, although there is a clear trend in sensitivity to MPS1 inhibition with BOS172722 between PTEN-deficient and PTEN-proficient cell lines, the difference was not statistically significant ( Figure 2A ). Treatment of 50 cancer cell lines from 8 different tissues of origin, in addition to the data we have generated using TNBC cell lines, showed that lung cancer cell lines overall
show similarly sensitivity to MPS1 inhibition (Supplementary Figure S2A ). In addition, similar to TNBC cell lines, the average doubling time of the cell lines above the median GI 50 was higher than the average doubling time of the cell lines below the median GI 50 . Moreover, there was a statistically significant difference between the doubling time of the most sensitive cell lines (top tercile, n=17, 38 hrs) relative to the rest of the cell lines (n=33, 53 hrs; Figure   2B ), suggesting that more rapidly dividing cells show greater susceptibility to MPS1 inhibition. Towards the identification of mutations that could predict sensitivity to BOS172722, we extracted non-silent mutations in the coding regions of genes for 16 sensitive cell lines (GI 50 < 50nM) and 16 resistant cell lines (GI 50 > 200nM) from the Cancer Cell Line Encyclopaedia (CCLE) database and looked for enrichment of mutated genes in the sensitive group.
We selected genes that were mutated in at least 3 cell lines in the sensitive group over the resistant group and in no more than two cell lines in the resistant group and calculated the fold enrichment in the two sets ( Supplementary Table S1B ). The most enriched mutated gene in the sensitive group was PI4KB, a protein that has been shown to be active in mitosis (38) and to prevent formation of polylobed nuclei (39) which is indicative of mitotic exit with aberrant chromosome segregation and aneuploidy ( Figure 2C ).
Similarly, mutations in ARID1A and SMARCA4 have been shown to induce genomic instability and aneuploidy (40) that is further increased to intolerable levels by MPS1 inhibition, resulting in cell death. In addition, mutations in NUMA1 and TPR, that have been shown to be involved in mitotic spindle assembly and in the activation of the SAC (41) (42) (43) , may directly sensitise cells to MPS1 inhibition.
We have previously shown that basal breast cancer cell lines (including TNBC) were more sensitive to our tool compound MPS1 inhibitor CCT271850 in comparison to luminal breast cancer cell lines (23) . To investigate further,
we used a panel of TNBC and non-TNBC cell lines to investigate the association between the potency of BOS172722 to: a) TNBC versus non-TNBC cell lines; b) MPS1 expression; c) proliferation rate and d) SAC activity.
We confirmed that TNBC cell lines are more sensitive to BOS172722 in comparison with non-TNBC cell lines (Supplementary Figure S2B and Supplementary Table S2 ). Our data from breast cancer cell lines are in agreement to the published data from primary breast tumours (44) that MPS1 expression is higher in TNBC versus non-TNBC cell lines ( Supplementary   Figures S2C,D) . Importantly, we found that the cellular potency of BOS172722 at Emax (representing maximum effect) significantly associated with the proliferation rate of the cell lines as measured by their doubling times ( Figure 2D ), similar to the panel of the 50 cell lines from different types of human cancers described above ( Figure 2B) ; TNBC cell lines, being more sensitive, have shorter doubling times (Supplementary Figure S2E) . We then investigated the association between BOS172722 potency and levels of SAC group. These data together suggest that the proliferation rate together with the SAC activity may potentially be used as stratification markers for TNBC patient selection to achieve maximum efficacy.
BOS172722 shows synergistic effect with paclitaxel in TNBC cell lines
Based on its promising in vitro profile, we progressed BOS172722, to human tumour xenograft models of TNBC to initially evaluate single agent efficacy. In established orthotopic MDA-MB-231 xenografts, BOS172722 given at 50mg/kg orally, twice a week for 47 days showed significant but moderate reduction of tumour growth compared with vehicle-treated mice (tumour growth inhibition: TGI = 66%, p = 0.0001; Supplementary Figure S3 ).
However, to support clinical trials as a single agent would require evidence of tumour stasis or regression in preclinical models. We therefore screened a panel of TNBC cell lines for synergism between BOS172722 with paclitaxel (Tax) at 1 and 2nM, doxorubicin (Dox) at 2 and 4nM and eribulin (Eri) at 0.1 and 0.2nM, to a wide range of BOS172722 concentrations (0 to 500nM). The data were then analysed using MacSynergyII (45) . Of the combinations of compounds tested, only paclitaxel with BOS172722 showed consistent synergy across our panel of TNBC cell lines ( Figure 3A) . By contrast, treatment of BOS172722 together with eribulin or doxorubicin did not show any synergy in the majority of the cell lines tested, with few exceptions ( Figure   3A ). We therefore focused on further characterising the mechanism of the synergism between BOS172722 and paclitaxel. In our screen, we used concentrations of 1 and 2nM of paclitaxel and the maximum synergism was observed at 1nM or <2nM for all cell lines ( Supplementary Table S3 ).
Importantly, the observed synergistic concentrations were relevant to the clinical concentrations of paclitaxel (46) . In addition, the paclitaxel concentrations where maximum synergy is observed are either at or below the respective GI 50 s of paclitaxel alone and are related to clinical dosing schedules (46) ( Supplementary Table S3 ).
In order to investigate the mechanism of action of the synergism of paclitaxel with BOS172722, we performed flow cytometry analysis of the cell cycle of MDA-MB-231 after treatment with each drug individually or in combination.
Treatment of MDA-MB-231 cells with 1nM paclitaxel or 100nM BOS172722
for 24h did not show any significant cell cycle effect on the cells. However, the combination of both agents led to a pronounced decrease in height and broadening of the G1 cell cycle peak, consistent with the induction of aneuploidy ( Figure 3B ). At these drug concentrations the cell cycle profile was completely abolished (an expected minor effect on the cell cycle histogram was observed at 2nM paclitaxel alone; Figure 3B ).
MPS1 inhibition reduces paclitaxel-induced mitotic delay and potentiates gross chromosome mis-segregation errors
The therapeutic effect of paclitaxel had long been attributed to the induction of a mitotic arrest (activating the SAC), resulting in cell death. Recent work however, demonstrated that paclitaxel exerts its effect mainly by the induction of aneuploidy via a multipolar mitosis (46) . In contrast, MPS1 inhibition leads to premature abrogation of the SAC and as a consequence, detrimental aneuploidy (7) .
We first assessed the abrogation of mitotic checkpoint by each drug, both individually and in combination using live cell microscopy of HeLa cells. ( Supplementary Figure S4B,C) .
Incubation of cells with BOS172722 resulted in a dose
Paclitaxel induces a weak mitotic checkpoint delay
Because we did not observe consistent synergy with eribulin in our initial screen, we then investigated whether a SAC which has been activated to the same extent by MT-depolymerizing or whether MT-stabilizing drugs shows a differential response to MPS1 inhibition. In order to achieve comparable checkpoint activation with microtubule depolymerizing and stabilizing agents, BOS172722 (4 times the concentration) in nocodazole-arrested cells. We therefore considered that the maximal SAC induced by microtubule depolymerizing agents is comparably stronger than the analogous SAC induced by paclitaxel. In line with this hypothesis, when we analysed the recruitment of BUB1 to the kinetochore by immunofluorescence, BUB1 levels were, on average markedly lower in the cells arrested with paclitaxel, being on average 50% of the levels seen in nocodazole and with a much larger range ( Figure 4B ). Taken together, these data, suggest that the override of the weak paclitaxel-induced SAC with low concentrations of BOS172722 may explain the synergistic increase in cell death.
Simultaneous combination of BOS172722 with paclitaxel for 24h induces maximum synergy
In order to better delineate the time that is required for the combination of paclitaxel and BOS172722 to exert a synergistic effect, we incubated MDA-MB-231 cells with BOS172722 for distinct periods of time and analysed the induced synergism with paclitaxel. We observed that incubation of both drugs for 12h had only a limited synergistic effect in MDA-MB-231 cells (Supplementary Figure S4D) . We then explored the synergy of paclitaxel and BOS172722 in association with the incubation time in wash-off long-term clonogenic assays in MDA-MB-231 cells. We found that the combination of 1nM paclitaxel with 10nM BOS172722 was as efficacious as higher concentrations of each individual drug ( Figure 4C ). We were also interested in investigating whether sequential addition of the drugs had any benefit over simultaneous treatment on the degree of synergism seen. The addition of BOS172722 following paclitaxel treatment or the opposite, had no superior effect over the simultaneous addition (Supplementary Figure S4E) . Therefore, simultaneous administration of drugs is potentially the most beneficial in clinical studies. Based on our data we propose the following model ( Figure   4D is a natural substrate of MPS1 and is phosphorylated upon initiation of SAC activation by MPS1 (47) .
Having shown that BOS172722 abrogates SAC as measured by paclitaxelinduced p-HH3 and p-KNL1 inhibition, we investigated whether we could identify target-engagement biomarkers to measure the activity of both paclitaxel and BOS172722 simultaneously in the same samples. It is known that taxanes induce acetylation of tubulin due to tubulin polymerisation (48), when at the same time MPS1 inhibition should not affect tubulin modification.
Paclitaxel and BOS172722 was administrated simultaneously into HCT116 tumour bearing mice. Figure 5C shows paclitaxel-induced acetylation of tubulin at all time points while addition of BOS172722 had no effect on tubulin acetylation. In contrast, paclitaxel-induced histone H3 phosphorylation was significantly inhibited by BOS172722 at 2 and 6h. To optimise these assays in a high throughput format, we developed quantitative electrochemiluminescence assays (MSD). The results confirmed the immunoblotting data, indicating a potential use of these biomarkers in the clinic ( Figure 5D ).
Therapeutic activity of BOS172722 in in vivo TNBC models
Based on in vitro activity and PD data, human TNBC xenograft experiments in athymic mice were undertaken to evaluate the therapeutic activity of paclitaxel alone or in combination with BOS172722. We initially used an MDA-MB-468 orthotopic (mouse mammary fat pad) xenograft model. Combination of BOS172722 with paclitaxel gave significant tumour regressions and a clear benefit in comparison with paclitaxel alone ( Figure 6A) . A study using a TNBC patient-derived xenograft (PDX) model also showed tumour regression and a significant benefit of combination treatment in comparison with paclitaxel alone ( Figure 6B ).
We then performed in vivo studies using a TNBC model to simulate breast cancer metastases. Tail-vein-injected MDA-MB-231-luciferase-expressing TNBC cells in SCID mice give rise predominantly to lung metastases. On day 28, the flux expressed as % of vehicle control was as follows: paclitaxel alone 18.8%; combination with BOS172722 at 30mg/kg 4.8% and 40mg/kg 5.7%
confirming a significant benefit of combination treatment in both tumour growth and survival (up to day 63) at BOS172722 doses ≥ 30mg/kg ( Figure   6C ,D). Taken together, the data described above demonstrate that our selective MPS1 inhibitor BOS172722 in combination with paclitaxel synergistically induces increased cell death in TNBC cell lines in vitro and regression and/or reduced growth rate of human tumour xenografts in vivo compared to treatment with either agent alone.
Discussion
We initially discovered MPS1 as a potential therapeutic target during a siRNA screening campaign where we showed that a subgroup of breast cancer cell lines with a deregulated PTEN tumour suppressor gene were susceptible to cell death upon MPS1 depletion (37) . We further investigated these findings Representative images of staining at 8h after treatment. C. Immunoblot analysis of tumour lysates from HCT116 xenografts in athymic mice treated with vehicle (V), Paclitaxel alone (P) or Paclitaxel in combination with BOS172722 (C). Antibodies against acetylated and total tubulin, phosphorylated and total histone H3 were used at the indicated time points. D. MSD assays to measure the level of acetylated tubulin and phosphorylated Histone H3 in HCT116 xenografts. 
